2-week course of sleep aid increases CPAP adherence in OSA patients at 6 months

May 17, 2009

ATS 2009, SAN DIEGO--New research suggests that patients newly diagnosed with obstructive sleep apnea (OSA) who use a short-course of the sleep aid, eszopiclone, when beginning continuous positive airway pressure (CPAP) therapy, are more adherent with therapy in six months.

The findings will be presented at the American Thoracic Society's International Conference in San Diego on May 17.

OSA is a common disorder that leads to multiple adverse effects on health and quality of life. CPAP is recommended as the first-line therapy for most patients with OSA, and has been shown to improve sleep quality, reduce daytime sleepiness and enhance quality of life. Despite its many benefits, however, compliance to CPAP is notoriously poor.

"We know that non-benzodiazepine sedative hypnotics promote sleep onset and continuity. Additionally, they can be safely used in patients with OSA, especially those already using CPAP," said Anita Shah, D.O., author of the study. "To date, the only consistently reliable predictor of long-term use has been compliance with CPAP at treatment initiation. Studies suggest that long-term adherence patterns may be established very early in the course of therapy."

To test whether eszopiclone would improve early CPAP adherence, the researchers conducted a prospective, double-blind, randomized, placebo-controlled trial involving patients newly diagnosed with OSA who were beginning CPAP therapy. A total of 154 patients were recruited into the study and were randomized to receive either eszopiclone or placebo for their first 14 days of CPAP therapy. CPAP adherence was measured weekly for 24 weeks. The study period began the first day of CPAP therapy.

At the conclusion of the study, researchers found significant differences between the eszopiclone group and the placebo group. On average, patients who received eszopiclone used their CPAP devices more nights per week, and for an hour longer per night. Although the sedative hypnotics were used for only two weeks, the increased adherence with CPAP was sustained for the entire six-month study period.

"Because we know that CPAP therapy improves sleep quality, reduces daytime sleepiness, enhances quality of life and may mitigate the excessive risk for cardiovascular events associated with this disorder, this small intervention could represent a profound clinical benefit to these patients," said Christopher Lettieri, M.D., principal investigator. "Given the poor adherence to CPAP therapy in many patients, any simple intervention that can reliably improve adherence should be strongly considered."

This study is part of the CPAP Promotion and Prognosis-The Army Sleep Apnea Program (CPAP ASAP Trial) being conducted at Walter Reed Army Medical Center. The CPAP ASAP Trial will examine multiple outcomes related to therapeutic adherence, health care utilization, co-morbid conditions and quality of life among patients with newly diagnosed OSA.
-end-


American Thoracic Society

Related Obstructive Sleep Apnea Articles from Brightsurf:

Obstructive sleep apnea risk varies in patients with different types of epilepsy
People with generalized epilepsy who have seizures arising from both sides of the brain simultaneously, have a higher risk of obstructive sleep apnea (OSA) compared to patients who have focal epilepsy where seizures emanate from one area of the brain, according to a Rutgers study.

Obstructive sleep apnoea: Mandibular advancement device helps against daytime sleepiness
Obstructive sleep apnoea: mandibular advancement device helps against daytime sleepiness In obstructive sleep apnoea, wearing a plastic splint in the mouth at night to keep the airways open mechanically is about as effective as positive airway pressure therapy with a sleep mask.

Study suggests women may be undertreated for obstructive sleep apnea
Here, we begin to drill down to understand how sleep apnea may differ and how common scoring approaches may underestimate sleep apnea in women.''

Obstructive sleep apnea may be one reason depression treatment doesn't work
When someone is depressed and having suicidal thoughts or their depression treatment just isn't working, their caregivers might want to check to see if they have obstructive sleep apnea, investigators say.

PET/CT detects cardiovascular disease risk factors in obstructive sleep apnea patients
Research presented at the Society of Nuclear Medicine and Molecular Imaging's 2019 Annual Meeting draws a strong link between severe obstructive sleep apnea (OSA) and impaired coronary flow reserve, which is an early sign of the heart disease atherosclerosis.

New evidence on the association of shortened sleep time and obstructive sleep apnea with sleepiness and cardiometabolic risk factors
A new study in the journal CHEST® may change the way we think about sleep disorders.

Obstructive sleep apnea and cardiovascular disease in women
Obstructive Sleep Apnea and Cardiovascular Disease in Women In the current issue of Cardiovascular Innovations and Applications (Special Issue on Women's Cardiovascular Health, Volume 3, Number 4, 2019, Guest Editor Gladys P.

Obstructive sleep apnea linked to inflammation, organ dysfunction
In the study, 'Obstructive Sleep Apnea and Inflammation: Proof of Concept Based on Two Illustrative Cytokines,' published recently in the International Journal of Molecular Sciences, researchers examined the link between obstructive sleep apnea syndrome (OSAS) and inflammation and the ensuing damage caused to organs.

Obstructive sleep apnea linked with higher risk of gout
New research reveals that people with obstructive sleep apnea (OSA) have a higher risk of developing gout, even beyond the first years after being diagnosed with the sleep disorder.

Blood biomarkers as a diagnostic tool for obstructive sleep apnea
Obstructive sleep apnea is a condition causing daytime tiredness which can significantly impact a patient's quality of life and increases the risk of cardiovascular disease and diabetes.

Read More: Obstructive Sleep Apnea News and Obstructive Sleep Apnea Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.